Treatment Patterns and Overall Survival (OS) Among Patients with Myelodysplastic Syndromes (MDS) Treated in the US Community Oncology Setting: A Real-World Retrospective Observational Study
So our study is a retrospective we call descriptive study, really looking at treatment patterns and outcomes in patients with myelodysplastic syndromes or MDS. So this is leveraging the data within the electronic health record called Ontada, which is within USOncology.
1,400 physicians taking care of patients
So again, reflective of the community based real world setting and it's a large database with over 1,400 physicians taking care of patients. So retrospective is this particular study. Back on patterns of care and outcomes in patients over a decade of time from 2011 through 2021.
We had over 2,700 patients and with MDS
So really looking back at you know, what how are these patients doing and how are we treating them in the community setting and. This is to our knowledge, the largest aggregate group of patients studied. We had over 2,700 patients and with MDS you know, this is a, we understand this to be an, a difficult disease space that primarily is in the elderly population and we've had limited therapy options.
Median age was 75 years old, about 40% women, 60% men
So, First, that the data set, I think, reflected the real world and that the median age was 75 years old, about 40% women, 60% men. And so importantly that that does reflect what we see, you know, in these patients. And when we're looking at retrospective and real world data we're really capturing what is an unselected population, you know, with clinical trials that we, first of all, A small percentage of the overall patients participate in clinical trials as important as they are to bring new therapies to us and to take care of our patients but they're also a more selected population. We know they don't represent the full demographics of America. and so translating that, To the real world. We have a lot of assumptions. and so it is important to look back at the retrospective data. And I think what the data that we were showing of importance was that the majority of patients with MDS have what we might call.
(click here for the rest of the transcript and video).
